ReviewCurrent allergy and asthma reports2015
Delayed Anaphylaxis Involving IgE to Galactose-alpha-1,3-galactose.
Review in Current allergy and asthma reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 62 citations in OpenAlex.
- Review
- Arming Inactivated Enveloped Virus Vaccines with theVaccines · 2026Review
- The α-Gal Epitope (Galα1-3Galβ1-4GlcNAc) as Therapeutic Agent in Cancer Immunotherapy, Vaccine Effectiveness Amplification and Injured Tissue Regeneration.International journal of molecular sciences · 2026Review
- Childhood-onset alpha-gal syndrome in the central black sea region: real-world data on diagnostic delays, age-specific clinical patterns, environmental risk factors, and anaphylaxis predictors.European journal of pediatrics · 2025Article
- Alpha-Gal Syndrome-A Series of Cases with Different Clinical Pictures.International journal of molecular sciences · 2025Article
- Intrinsic risk factors for alpha-gal syndrome in a case-control study, 2019 to 2020.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2024Article
- Tick bite as a risk factor for alpha-gal-specific immunoglobulin E antibodies and development of alpha-gal syndrome.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2023Article
- Poly-L-Lysine-Based αGal-Glycoconjugates for Treating Anti-αGal IgE-Mediated Diseases.Frontiers in immunology · 2022Article
- Biomanufacturing of Axon-Based Tissue Engineered Nerve Grafts Using Porcine GalSafe Neurons.Tissue engineering. Part A · 2021Article
- Biosynthesis of α-Gal Epitopes (Galα1-3Galβ1-4GlcNAc-R) and Their Unique Potential in Future α-Gal Therapies.Frontiers in molecular biosciences · 2021Review
- Tick Saliva and the Alpha-Gal Syndrome: Finding a Needle in a Haystack.Frontiers in cellular and infection microbiology · 2021Review
- Delayed urticaria or anaphylaxis after consumption of red meat with evidence of alpha-gal sensitisation.BMJ case reports · 2020Article
- Article
- Global Trends in Anaphylaxis Epidemiology and Clinical Implications.The journal of allergy and clinical immunology. In practice · 2020Article
- New Perspectives in Food Allergy.International journal of molecular sciences · 2020Review
- Possible Role of Environmental Factors in the Development of Food Allergies.Clinical reviews in allergy & immunology · 2019Review
- Parasites and allergy: Observations from Africa.Parasite immunology · 2019Review
- [Diagnostics of alpha-gal syndrome : Current standards, pitfalls and perspectives].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2019Review
- Environmental and Molecular Drivers of the α-Gal Syndrome.Frontiers in immunology · 2019Review
- Tick galactosyltransferases are involved in α-Gal synthesis and play a role during Anaplasma phagocytophilum infection and Ixodes scapularis tick vector development.Scientific reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Hypersensitivity in the allergic setting refers to immune reactions, stimulated by soluble antigens that can be rapidly progressing and, in the case of anaphylaxis, are occasionally fatal. As the number of known exposures associated with anaphylaxis is limited, identification of novel causative agents is important in facilitating both education and other allergen-specific approaches that are crucial to long-term risk management. Within the last 10 years, several seemingly separate observations were recognized to be related, all of which resulted from the development of antibodies to a carbohydrate moiety on proteins where exposure differed from airborne allergens but which were nevertheless capable of producing anaphylactic and hypersensitivity reactions. Our recent work has identified these responses as being due to a novel IgE antibody directed against a mammalian oligosaccharide epitope, galactose-alpha-1,3-galactose (alpha-gal). This review will present the history and biology of alpha-gal and discuss our current approach to management of the mammalian meat allergy and delayed anaphylaxis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.